Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report by M. D’Aveni-Piney, M. Divoux, H. Busby-Venner, M. Muller, J. Broséus, P. Feugier

Subjects: Get full text

BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA by Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

Subjects: “…Chronic lymphocytic leukemia, ibrutinib, idelalisib, toxicity, safety…”
Get full text

Prognosis and new therapeutic approaches in chronic lymphocytic leukemia treatment by Otašević Vladimir, Mihaljević Biljana, Antić Darko

Subjects: Get full text

Idelalisib may have the potential to increase radiotherapy side effects by Thomas Gryc, Florian Putz, Nicole Goerig, Sonia Ziegler, Rainer Fietkau, Luitpold V. Distel, Barbara Schuster

Subjects: “…Idelalisib…”
Get full text

Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome by Surya K. De, Surya K. De

Subjects: “…idelalisib…”
Get full text

RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY? by Antonio Cuneo, Robin Foà

Subjects: “…Chronic lymphocytic leukemia; finite-duration treatment; venetoclax; ibrutinib; idelalisib…”
Get full text

The Effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on the Expression of Immune Checkpoint Ligands in Acute Myeloid Leukemia Cell Line by Saeid Taghiloo, Saeid Norozi, Hossein Asgarian-Omran

Subjects: Get full text

Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia by Jingmei Yang, Ran Friedman

Subjects: Get full text

Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis by Stephanos Vassilopoulos, Stephanos Vassilopoulos, Fadi Shehadeh, Fadi Shehadeh, Fadi Shehadeh, Markos Kalligeros, Markos Kalligeros, Quynh-Lam Tran, Quynh-Lam Tran, Fred Schiffman, Fred Schiffman, Eleftherios Mylonakis, Eleftherios Mylonakis

Subjects: Get full text

Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma by Hiroo Katsuya, Lucy B. M. Cook, Aileen G. Rowan, Yorifumi Satou, Graham P. Taylor, Charles R. M. Bangham

Subjects: Get full text

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas by Madanat YF, Smith MR, Almasan A, Hill BT

Subjects: “…Idelalisib…”
Get full text

Impact of Selected Small-Molecule Kinase Inhibitors on Lipid Membranes by Meike Luck, Markus Fischer, Maximilian Werle, Holger A. Scheidt, Peter Müller

Subjects: Get full text

Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative ef... by L.-M. Sklarz, Y. S. Gladbach, M. Ernst, M. Hamed, C. Roolf, S. Sender, J. Beck, E. Schütz, S. Fischer, S. Struckmann, C. Junghanss, G. Fuellen, H. Murua Escobar

Subjects: Get full text

Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report by Salma Machan, Carlos Plaza, Yosmar Pérez-González, Maria Rodriguez-Pinilla, Luis Requena, Raul Cordoba

Subjects: Get full text

Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome by Ojeda-Uribe M, Rimelen V, Marzullo C

Subjects: Get full text

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression by Lisa Rohrbacher, Lisa Rohrbacher, Bettina Brauchle, Bettina Brauchle, Ana Ogrinc Wagner, Ana Ogrinc Wagner, Michael von Bergwelt-Baildon, Michael von Bergwelt-Baildon, Michael von Bergwelt-Baildon, Veit L. Bücklein, Veit L. Bücklein, Marion Subklewe, Marion Subklewe, Marion Subklewe

Subjects: Get full text

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial by Marco Montillo, Árpád Illés, Tadeusz Robak, Alexander S. Pristupa, Malgorzata Wach, Miklós Egyed, Julio Delgado, Wojciech Jurczak, Franck Morschhauser, Anna Schuh, Herbert Eradat, Sanatan Shreay, Jacqueline C. Barrientos, Andrew D. Zelenetz

Subjects: “…Idelalisib…”
Get full text

Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers by Siyoung Ha, Himali Gujrati, Bi-Dar Wang, Bi-Dar Wang

Subjects: Get full text

Hide and Seek: The Game Between Chronic Lymphocytic Leukaemia Cells and B Cell Receptor Signalling Inhibitors by Kumudha Balakrishnan, Krishna Bojja, William Decker, Michael J. Keating

Subjects: Get full text